Abstract
NSAIDs represent one of the most commonly used therapeutic drug groups worldwide. 1.5percent of the world population is estimated as taking NSAIDs. However, their use is not risk free and gastrointestinal (GI) lesions do appear, which is indeed the main reason for their toxicity. Frequently (50percent) NSAID-induced GI-Lesions are asymptomatic, 71percent of GI perforations and 50percent of upper gastric hemorrhages (UGH) are associated with taking NSAIDs How frequent GI lesions appear is directly related to whether the patient is in a risk group or not. Factors increasing the risk of GI lesions occurring are the following: being older than 60, using corticoids or other NSAIDs concomitantly, having a history of duodenal ulcer, alcohol consumption, smoking or taking oral anticoagulants. As the toxicity and how frequent the lesions appear depend on which drug is used, there is a need for research into new drugs which are both clinically effective and safer to use. GI toxicity of NSAIDs is mediated by two mechanisms, direct toxicity and prostaglandin synthesis inhibition or sistemic mechanism. Due to the relatively recent discoveries concerning the physiopathology of inflammation and gastric physiology, research into new NSAID derivatives is taking place. Such derivatives are prodrugs, galenic buffer forms, selective COX-2 inhibitors, isomeric compounds, NO-donors, and as a future possibility, phosphodiesterase inhibitors.
Keywords: Antiinflamatory Agents Less, Gastrointestinal Tract, COX-2 inhibitors, cyclooxygenase-2 COX-2, Polymorphouuclear leukocyte, PMN-endothelial cell, Intercellular adhesion molecular 1 ICAM, Water immersion restraint WIR, Oxidative Metabolism
Current Pharmaceutical Design
Title: Antiinflamatory Agents Less Dangerous for Gastrointestinal Tract
Volume: 7 Issue: 10
Author(s): M. Rodriguez-Tellez, F. Arguelles, J. M. Herrerias, Jr., D. Ledro, J. Esteban and J. M. Herrerias
Affiliation:
Keywords: Antiinflamatory Agents Less, Gastrointestinal Tract, COX-2 inhibitors, cyclooxygenase-2 COX-2, Polymorphouuclear leukocyte, PMN-endothelial cell, Intercellular adhesion molecular 1 ICAM, Water immersion restraint WIR, Oxidative Metabolism
Abstract: NSAIDs represent one of the most commonly used therapeutic drug groups worldwide. 1.5percent of the world population is estimated as taking NSAIDs. However, their use is not risk free and gastrointestinal (GI) lesions do appear, which is indeed the main reason for their toxicity. Frequently (50percent) NSAID-induced GI-Lesions are asymptomatic, 71percent of GI perforations and 50percent of upper gastric hemorrhages (UGH) are associated with taking NSAIDs How frequent GI lesions appear is directly related to whether the patient is in a risk group or not. Factors increasing the risk of GI lesions occurring are the following: being older than 60, using corticoids or other NSAIDs concomitantly, having a history of duodenal ulcer, alcohol consumption, smoking or taking oral anticoagulants. As the toxicity and how frequent the lesions appear depend on which drug is used, there is a need for research into new drugs which are both clinically effective and safer to use. GI toxicity of NSAIDs is mediated by two mechanisms, direct toxicity and prostaglandin synthesis inhibition or sistemic mechanism. Due to the relatively recent discoveries concerning the physiopathology of inflammation and gastric physiology, research into new NSAID derivatives is taking place. Such derivatives are prodrugs, galenic buffer forms, selective COX-2 inhibitors, isomeric compounds, NO-donors, and as a future possibility, phosphodiesterase inhibitors.
Export Options
About this article
Cite this article as:
Rodriguez-Tellez M., Arguelles F., Herrerias, Jr. M. J., Ledro D., Esteban J. and Herrerias M. J., Antiinflamatory Agents Less Dangerous for Gastrointestinal Tract, Current Pharmaceutical Design 2001; 7 (10) . https://dx.doi.org/10.2174/1381612013397663
DOI https://dx.doi.org/10.2174/1381612013397663 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oligomerization of G Protein-Coupled Receptors: Computational Methods
Current Medicinal Chemistry Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter
Current Pharmaceutical Design Orphan Nuclear Receptors, Excellent Targets of Drug Discovery
Combinatorial Chemistry & High Throughput Screening Improving Brain Drug Targeting Through Exploitation of The Nose-to- Brain Route: A Physiological and Pharmacokinetic Perspective
Current Drug Delivery There is no Failure, Only Discovery—the Year Ahead for CARving New Paths
Current Alzheimer Research Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Antibodies Against G-Protein Coupled Receptors: Novel Uses in Screening and Drug Development
Combinatorial Chemistry & High Throughput Screening Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Matrix Mechanics and Fluid Shear Stress Control Stem Cells Fate in Three Dimensional Microenvironment
Current Stem Cell Research & Therapy Editorial [Hot Topic: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy (Guest Editor: Marie Ranson)]
Current Drug Targets Mechanistic Overview of Immune Modulatory Effects of Environmental Toxicants
Inflammation & Allergy - Drug Targets (Discontinued) Tachykinins and their Receptors in Human Malignancies
Current Drug Targets HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Optimization of Spotting Buffer for Polystyrene Based ELISA Arrays
Current Analytical Chemistry Targeting Protein Kinase C (PKC) in Physiology and Cancer of the Gastric Cell System
Current Medicinal Chemistry Identification of Expressed miRNAs in Human Rheumatoid Arthritis Using Computational Approach – Discovery of a New miR-7167 from Human
MicroRNA PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives
Current Molecular Pharmacology Molecular Insight into the Crosstalk of UPS Components and Alzheimer’s Disease
Current Protein & Peptide Science Terpenoids and Glycolipids from Euphorbiaceae
Mini-Reviews in Medicinal Chemistry